The EU competition authority did not provide details of Pfizer’s proposal, in line with its policy. It extended the deadline for its decision to Aug. 4 from July 20 to examine the concessions.
It can either clear the deal, if it decides Pfizer has allayed competition concerns, or open a full-scale investigation.
Pfizer, maker of impotence treatment Viagra and cholesterol drug Lipitor, is making its biggest-ever acquisition aimed at expanding its portfolio of generic injectable drugs and copies of biotech medicines.
Hospira makes generic versions of injectable drugs used in hospitals, pumps to deliver such medicine and also sells biosimilars or copies of biotech drugs.